AAPL 252.355 -1.2657% MSFT 425.34 -1.2055% NVDA 137.935 0.6751% GOOGL 191.5586 -0.6233% GOOG 192.78 -0.6494% AMZN 221.06 -1.2022% META 595.1101 -0.7836% AVGO 235.435 -2.6122% TSLA 423.545 -1.88% TSM 200.0799 -0.7688% LLY 777.045 -0.7821% V 315.925 -0.8583% JPM 239.24 -0.8003% UNH 506.325 -0.7186% NVO 86.49 -1.0072% WMT 90.6201 -1.1345% LVMUY 130.5 -1.368% XOM 105.8 -0.6386% LVMHF 654.0 -1.5794% MA 525.18 -1.3191%
Last update at 2024-12-30T16:53:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -95.94000M | -128.18900M | -108.38200M | -52.17900M | -13.93300M |
| Minority interest | - | - | - | - | - |
| Net income | -96.04600M | -128.33200M | -108.54300M | -52.26400M | -13.93300M |
| Selling general administrative | 26.41M | 28.53M | 17.94M | 10.01M | 3.21M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 13.91M | 4.36M | -10.54800M | - | - |
| Reconciled depreciation | 3.67M | 3.78M | 3.33M | 2.30M | 1.29M |
| Ebit | -101.25500M | -132.09900M | -101.15900M | -54.04300M | -13.66100M |
| Ebitda | -97.58000M | -128.32100M | -97.83400M | -51.74400M | -12.37000M |
| Depreciation and amortization | 3.67M | 3.78M | 3.33M | 2.30M | 1.29M |
| Non operating income net other | -0.05700M | -0.10900M | - | - | - |
| Operating income | -97.58000M | -128.32100M | -97.83400M | -54.04300M | -13.66100M |
| Other operating expenses | 111.49M | 132.68M | 97.83M | 54.04M | 13.66M |
| Interest expense | 1.64M | 0.13M | 10.55M | 1.86M | 0.00000M |
| Tax provision | 0.11M | 0.14M | 0.16M | 0.09M | 0.00000M |
| Interest income | 1.64M | 0.13M | - | 1.56M | 0.16M |
| Net interest income | 1.64M | 0.13M | -10.54800M | 1.56M | 0.16M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.11M | 0.14M | 0.16M | 0.09M | -0.27200M |
| Total revenue | 13.91M | 4.36M | -10.54800M | 0.00000M | 0.00000M |
| Total operating expenses | 111.49M | 132.68M | 97.83M | 54.04M | 13.66M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 1.64M | 0.13M | -10.54800M | 1.86M | -0.43500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -96.04600M | -128.33200M | -108.54300M | -52.26400M | -13.93300M |
| Net income applicable to common shares | -96.04600M | -128.33200M | -108.54300M | -52.26400M | -15.19964M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 153.90M | 146.69M | 235.37M | 265.30M | 146.52M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 5.31M | 7.72M | 13.69M | 5.94M | 2.02M |
| Total liab | 61.82M | 42.79M | 50.64M | 45.26M | 211.41M |
| Total stockholder equity | 92.08M | 103.90M | 184.73M | 220.04M | -64.89100M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 16.84M | 16.04M | 25.39M | 16.56M | 0.75M |
| Common stock | 0.00700M | 0.00400M | 0.00400M | 0.00400M | 0.00400M |
| Capital stock | 0.00700M | 0.00400M | 0.00400M | 0.00400M | 0.00000M |
| Retained earnings | -486.79700M | -399.11800M | -303.07200M | -174.74000M | -66.19700M |
| Other liab | - | 0.23M | 0.13M | 4.49M | 3.63M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.63M | 0.87M | 0.00728M | 0.19M |
| Cash | 135.77M | 81.35M | 186.82M | 220.38M | 69.56M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 23.91M | 33.13M | 38.96M | 30.27M | 13.82M |
| Current deferred revenue | 1.31M | 9.21M | 7.64M | 7.89M | 6.85M |
| Net debt | -124.63600M | -68.77300M | -172.36100M | -207.37600M | -55.23400M |
| Short term debt | 3.24M | 3.14M | 2.91M | 2.51M | 2.45M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 11.14M | 12.57M | 14.46M | 13.01M | 14.33M |
| Other stockholder equity | 578.33M | 355.92M | 251.98M | 129.66M | 1.42M |
| Property plant equipment | - | 4.82M | 14.97M | 14.91M | 16.09M |
| Total current assets | 141.08M | 133.54M | 204.42M | 250.02M | 120.23M |
| Long term investments | - | 0.00000M | 15.11M | 0.00000M | 10.02M |
| Net tangible assets | - | 103.90M | 184.73M | 220.04M | -64.89100M |
| Short term investments | 0.00000M | 44.48M | 3.92M | 23.13M | 48.10M |
| Net receivables | - | - | - | - | - |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 2.52M | 4.74M | 3.02M | 3.31M | 3.77M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.55M | 0.40M | 0.45M | -0.18800M | -0.11500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00400M | 0.00400M | 0.00400M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -399.11800M | -303.07200M | -174.74000M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.62M | 0.63M | 0.87M | 0.38M | 0.19M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 12.82M | 13.15M | 30.95M | 15.29M | 26.29M |
| Capital lease obligations | 11.14M | 12.57M | 14.46M | 13.01M | 14.33M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -25.35000M | 3.91M | 32.76M | 6.79M | -69.28900M |
| Change to liabilities | -5.04900M | -4.67200M | 11.87M | 0.39M | 3.25M |
| Total cashflows from investing activities | -26.29300M | 3.02M | 32.76M | 6.79M | -75.58799M |
| Net borrowings | -0.06100M | -0.07900M | -0.05800M | -0.04300M | 5.45M |
| Total cash from financing activities | 0.16M | 78.68M | 192.35M | 85.53M | 99.89M |
| Change to operating activities | -5.77600M | 0.02M | 4.19M | 3.29M | 2.08M |
| Net income | -96.04600M | -128.33200M | -108.54300M | -52.26400M | -13.93300M |
| Change in cash | -105.51800M | -33.96300M | 150.84M | 45.56M | 24.55M |
| Begin period cash flow | 186.98M | 220.94M | 70.10M | 24.55M | 0.00000M |
| End period cash flow | 81.46M | 186.98M | 220.94M | 70.10M | 24.55M |
| Total cash from operating activities | -79.38900M | -115.66200M | -74.26300M | -46.76700M | -6.04900M |
| Issuance of capital stock | 0.00000M | 78.58M | 195.54M | 84.96M | 94.81M |
| Depreciation | 3.67M | 3.78M | 3.33M | 2.30M | 1.29M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | 0.23M | 79.63M | 156.93M | - | - |
| Other cashflows from financing activities | 0.20M | 0.17M | 36.86M | 85.58M | 99.88M |
| Change to netincome | 14.69M | 13.54M | 14.89M | -0.47300M | 1.33M |
| Capital expenditures | 0.94M | 0.89M | 2.06M | 2.79M | 2.52M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | 4.87M | -13.07600M | 18.60M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -105.51800M | -33.96300M | 150.84M | - | - |
| Change in working capital | -1.55200M | -4.65100M | 16.06M | 3.67M | 4.88M |
| Stock based compensation | 14.69M | 13.46M | 2.98M | 0.75M | 0.18M |
| Other non cash items | -0.15900M | 0.09M | 11.39M | -1.22500M | 1.64M |
| Free cash flow | -80.33200M | -116.55400M | -76.32700M | -49.55300M | -8.56500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALGS Aligos Therapeutics Inc |
-1.8173 4.42% | 39.33 | - | - | 16.49 | 2.05 | 6.18 | 0.57 |
| NVO Novo Nordisk A/S |
-0.88 1.01% | 86.49 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.09 2.37% | 86.05 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-7.5529 1.85% | 401.21 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-8.0 1.12% | 704.40 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
One Corporate Drive, South San Francisco, CA, United States, 94080
| Name | Title | Year Born |
|---|---|---|
| Dr. Lawrence M. Blatt MBA, Ph.D. | CEO & Chairman | 1962 |
| Dr. Leonid Beigelman Ph.D. | Pres & Director | 1959 |
| Dr. Julian A. Symons DPHIL | Exec. VP & Chief Scientific Officer | 1961 |
| Ms. Lesley Ann Calhoun CPA | Exec. VP & CFO | 1966 |
| Ms. Lucinda Y. Quan J.D. | Exec. VP, Chief Bus. Officer & Gen. Counsel | 1972 |
| Kristina Engeseth | Exec. Director and Head of People & Culture | NA |
| Mr. John Fry | Exec. VP of Clinical Devel. | 1963 |
| Dr. Matthew W. McClure M.D. | Exec. VP & Chief Medical Officer | 1972 |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Exec. VP of Translational Safety Sciences | 1966 |
| Dr. David B. Smith Ph.D. | Exec. VP & Head of Chemical Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...